Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Roy S. Herbst, Jean‐Charles Soria, Marcin Kowanetz et al. · Nature · 2014
Cited by 5,222 works. doi:10.1038/nature14011
Authors
- Roy S. Herbst
- Jean‐Charles Soria
- Marcin Kowanetz
- Gregg Daniel Fine
- Omid Hamid
- Michael S. Gordon
- Jeffrey Alan Sosman
- David F. McDermott
- John D. Powderly
- Scott N. Gettinger
- Holbrook E K Kohrt
- Leora Horn
- Donald P. Lawrence
- Sandra Rost
- Maya K. Leabman
- Yuanyuan Xiao
- Ahmad Mokatrin
- Hartmut Koeppen
- Priti S. Hegde
- Ira Mellman
References
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
- Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion
- Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria
- Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
- B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion
- Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape